|irazyr (icatibant injection)
||Firazyr is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. Firazyr provides a new option to treat acute attacks of HAE because it is the first HAE treatment that can be self-administered.
||Xalkori is indicated to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers who express the abnormal anaplastic lymphoma kinase (ALK) gene. (Xalkori’s companion diagnostic test, the Vysis ALK Break Apart FISH Probe Kit, tests for the ALK gene.)
||Pharmacy benefit (quantity limit of 60 tablets/30 days)
||Zelboraf is indicated to treat patients with late-stage (metastatic) or unresectable melanoma. Zelboraf is specifically indicated for the treatment of patients with melanoma whose tumors express a gene mutation called BRAF V600E. (Zelboraf’s companion diagnostic test, the cobas 4800 BRAF V600 Mutation Test, tests for the BRAF V600E mutation.)
||Nulojix is indicated to prevent acute rejection in adult patients who have had a kidney transplant.
|H.P. Acthar Gel (repository corticotropin injection)
||H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue used to treat infantile spasms, multiple sclerosis exacerbations, and nephrotic syndrome.